| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Practice Guidelines as Topic | 27 | 2024 | 1096 | 5.620 |
Why?
|
| Evidence-Based Medicine | 8 | 2024 | 458 | 1.720 |
Why?
|
| Priapism | 2 | 2023 | 7 | 1.020 |
Why?
|
| Humans | 92 | 2024 | 95992 | 0.920 |
Why?
|
| Early Detection of Cancer | 3 | 2021 | 484 | 0.870 |
Why?
|
| Diabetes Mellitus | 2 | 2024 | 771 | 0.800 |
Why?
|
| Societies, Medical | 10 | 2024 | 645 | 0.800 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2024 | 187 | 0.790 |
Why?
|
| Hypoglycemia | 1 | 2024 | 112 | 0.790 |
Why?
|
| Cardiology | 3 | 2020 | 134 | 0.760 |
Why?
|
| Ambulatory Care | 1 | 2024 | 198 | 0.750 |
Why?
|
| Erectile Dysfunction | 1 | 2023 | 79 | 0.750 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2021 | 2 | 0.710 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2021 | 3 | 0.710 |
Why?
|
| Ferritins | 1 | 2021 | 31 | 0.710 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2021 | 22 | 0.700 |
Why?
|
| Long QT Syndrome | 3 | 2016 | 41 | 0.700 |
Why?
|
| Varenicline | 1 | 2021 | 16 | 0.670 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2021 | 92 | 0.660 |
Why?
|
| Macrolides | 1 | 2020 | 31 | 0.630 |
Why?
|
| Fluoroquinolones | 1 | 2020 | 20 | 0.630 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2018 | 1230 | 0.630 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2022 | 111 | 0.630 |
Why?
|
| beta-Lactams | 1 | 2020 | 15 | 0.630 |
Why?
|
| Cancer Survivors | 1 | 2021 | 88 | 0.630 |
Why?
|
| Smoking Prevention | 2 | 2016 | 46 | 0.620 |
Why?
|
| Lubricants | 1 | 2019 | 8 | 0.620 |
Why?
|
| Laxatives | 1 | 2019 | 13 | 0.620 |
Why?
|
| Testosterone | 2 | 2018 | 276 | 0.620 |
Why?
|
| Tobacco Use Disorder | 1 | 2021 | 122 | 0.610 |
Why?
|
| Smoking Cessation | 3 | 2016 | 272 | 0.610 |
Why?
|
| Menorrhagia | 1 | 2020 | 28 | 0.610 |
Why?
|
| Sudden Infant Death | 2 | 2016 | 34 | 0.570 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2018 | 18 | 0.560 |
Why?
|
| Hair Removal | 1 | 2018 | 14 | 0.560 |
Why?
|
| Pneumonia | 1 | 2020 | 196 | 0.560 |
Why?
|
| Coronary Artery Disease | 6 | 2022 | 395 | 0.550 |
Why?
|
| Hirsutism | 1 | 2018 | 61 | 0.550 |
Why?
|
| Incidental Findings | 1 | 2018 | 99 | 0.550 |
Why?
|
| Algorithms | 2 | 2017 | 2018 | 0.550 |
Why?
|
| Hypercholesterolemia | 1 | 2019 | 161 | 0.540 |
Why?
|
| Hypogonadism | 1 | 2018 | 44 | 0.540 |
Why?
|
| Gender Dysphoria | 1 | 2017 | 10 | 0.540 |
Why?
|
| Aftercare | 1 | 2018 | 90 | 0.540 |
Why?
|
| Physician-Patient Relations | 4 | 2020 | 636 | 0.540 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2017 | 50 | 0.530 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2018 | 139 | 0.530 |
Why?
|
| Sepsis | 2 | 2024 | 389 | 0.530 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2024 | 395 | 0.520 |
Why?
|
| Stroke Rehabilitation | 1 | 2018 | 50 | 0.520 |
Why?
|
| Mass Screening | 4 | 2015 | 710 | 0.520 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 2777 | 0.520 |
Why?
|
| Adult | 24 | 2024 | 28636 | 0.520 |
Why?
|
| Androgen Antagonists | 1 | 2018 | 144 | 0.510 |
Why?
|
| Travel | 1 | 2017 | 73 | 0.510 |
Why?
|
| Organizations | 1 | 2017 | 17 | 0.510 |
Why?
|
| Colonoscopy | 1 | 2019 | 304 | 0.510 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2017 | 50 | 0.510 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 169 | 0.500 |
Why?
|
| Diarrhea | 1 | 2017 | 180 | 0.490 |
Why?
|
| Thyroid Nodule | 1 | 2017 | 60 | 0.480 |
Why?
|
| United States | 19 | 2024 | 7785 | 0.480 |
Why?
|
| Papillomavirus Infections | 2 | 2021 | 301 | 0.480 |
Why?
|
| Shock, Septic | 1 | 2017 | 125 | 0.470 |
Why?
|
| Health Services for the Aged | 1 | 2015 | 32 | 0.460 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 265 | 0.460 |
Why?
|
| Disease Management | 6 | 2019 | 363 | 0.460 |
Why?
|
| Papillomavirus Vaccines | 2 | 2021 | 59 | 0.460 |
Why?
|
| Hepatitis C Antibodies | 1 | 2015 | 8 | 0.460 |
Why?
|
| Behavior Therapy | 1 | 2016 | 95 | 0.460 |
Why?
|
| Constipation | 1 | 2016 | 69 | 0.450 |
Why?
|
| Seizures | 2 | 2020 | 331 | 0.440 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 514 | 0.440 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2017 | 198 | 0.440 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 43 | 0.430 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 425 | 0.430 |
Why?
|
| Urinary Incontinence | 1 | 2017 | 217 | 0.430 |
Why?
|
| Residence Characteristics | 1 | 2016 | 213 | 0.430 |
Why?
|
| Counseling | 1 | 2016 | 174 | 0.430 |
Why?
|
| Physicians | 2 | 2020 | 707 | 0.420 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2018 | 68 | 0.420 |
Why?
|
| Bariatric Surgery | 1 | 2017 | 207 | 0.420 |
Why?
|
| Quality Improvement | 3 | 2015 | 502 | 0.420 |
Why?
|
| Hypertension | 2 | 2017 | 775 | 0.410 |
Why?
|
| Carotid Stenosis | 1 | 2015 | 115 | 0.410 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2015 | 121 | 0.410 |
Why?
|
| Recurrence | 1 | 2016 | 1231 | 0.400 |
Why?
|
| Quality of Health Care | 3 | 2013 | 403 | 0.390 |
Why?
|
| Hepatitis C | 1 | 2015 | 184 | 0.390 |
Why?
|
| Vaccination | 1 | 2014 | 310 | 0.370 |
Why?
|
| Colorectal Neoplasms | 2 | 2019 | 1069 | 0.370 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 443 | 0.370 |
Why?
|
| Lung | 1 | 2018 | 1380 | 0.360 |
Why?
|
| Female | 36 | 2024 | 49980 | 0.350 |
Why?
|
| Tachycardia, Ventricular | 3 | 2022 | 180 | 0.350 |
Why?
|
| Male | 33 | 2024 | 45792 | 0.340 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 2385 | 0.320 |
Why?
|
| Health Care Reform | 1 | 2011 | 86 | 0.310 |
Why?
|
| Stroke | 2 | 2018 | 1089 | 0.300 |
Why?
|
| American Heart Association | 3 | 2024 | 110 | 0.280 |
Why?
|
| Cardiovascular Diseases | 3 | 2016 | 778 | 0.270 |
Why?
|
| Electrocardiography | 5 | 2022 | 559 | 0.260 |
Why?
|
| Health Maintenance Organizations | 3 | 1999 | 20 | 0.260 |
Why?
|
| Risk | 3 | 2024 | 666 | 0.250 |
Why?
|
| Attitude to Health | 2 | 1999 | 226 | 0.250 |
Why?
|
| Infant | 9 | 2024 | 3359 | 0.240 |
Why?
|
| Healthcare Disparities | 3 | 2010 | 492 | 0.240 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2018 | 107 | 0.230 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2024 | 116 | 0.230 |
Why?
|
| Australia | 7 | 2020 | 125 | 0.210 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2024 | 12 | 0.210 |
Why?
|
| Vaginal Smears | 2 | 2021 | 71 | 0.210 |
Why?
|
| Coronary Disease | 2 | 2024 | 263 | 0.210 |
Why?
|
| Risk Factors | 9 | 2018 | 5992 | 0.210 |
Why?
|
| Thiophenes | 1 | 2024 | 45 | 0.210 |
Why?
|
| Meteoroids | 1 | 2023 | 1 | 0.200 |
Why?
|
| Heart Valve Diseases | 2 | 2024 | 122 | 0.200 |
Why?
|
| Antirheumatic Agents | 1 | 2024 | 61 | 0.200 |
Why?
|
| Aortic Diseases | 1 | 2024 | 104 | 0.190 |
Why?
|
| Middle Aged | 17 | 2024 | 28299 | 0.190 |
Why?
|
| Penis | 1 | 2023 | 65 | 0.190 |
Why?
|
| Carbon | 1 | 2023 | 97 | 0.190 |
Why?
|
| Quinazolines | 1 | 2024 | 216 | 0.190 |
Why?
|
| Sex Factors | 4 | 2021 | 1130 | 0.190 |
Why?
|
| Standard of Care | 1 | 2023 | 70 | 0.190 |
Why?
|
| Infertility, Male | 1 | 2022 | 28 | 0.190 |
Why?
|
| Risk Assessment | 5 | 2018 | 2498 | 0.190 |
Why?
|
| Nadolol | 1 | 2022 | 5 | 0.190 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2024 | 187 | 0.180 |
Why?
|
| Patient Care | 1 | 2023 | 101 | 0.180 |
Why?
|
| Drug Therapy, Combination | 2 | 2024 | 789 | 0.180 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2021 | 4 | 0.180 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 2384 | 0.180 |
Why?
|
| Heart Transplantation | 3 | 2018 | 816 | 0.180 |
Why?
|
| Gout Suppressants | 1 | 2021 | 35 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 935 | 0.180 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2024 | 208 | 0.180 |
Why?
|
| Liver Failure, Acute | 1 | 2021 | 39 | 0.170 |
Why?
|
| Physicians, Primary Care | 3 | 2012 | 110 | 0.170 |
Why?
|
| Liver Cirrhosis | 2 | 2024 | 276 | 0.170 |
Why?
|
| Diagnostic Imaging | 5 | 2024 | 476 | 0.170 |
Why?
|
| Ultrasonography | 3 | 2024 | 747 | 0.170 |
Why?
|
| Child | 11 | 2024 | 7621 | 0.170 |
Why?
|
| Gout | 1 | 2021 | 75 | 0.170 |
Why?
|
| Postmenopause | 1 | 2021 | 107 | 0.170 |
Why?
|
| Endocarditis | 1 | 2021 | 25 | 0.170 |
Why?
|
| Defibrillators, Implantable | 2 | 2018 | 190 | 0.170 |
Why?
|
| Myocardial Contusions | 1 | 2020 | 2 | 0.170 |
Why?
|
| Pancreatic Cyst | 1 | 2021 | 29 | 0.170 |
Why?
|
| Iron | 1 | 2021 | 179 | 0.170 |
Why?
|
| Foot Deformities, Congenital | 1 | 2020 | 11 | 0.170 |
Why?
|
| Optic Atrophy | 1 | 2020 | 5 | 0.170 |
Why?
|
| Hemiplegia | 1 | 2020 | 17 | 0.170 |
Why?
|
| Reflex, Abnormal | 1 | 2020 | 7 | 0.170 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2021 | 114 | 0.160 |
Why?
|
| Smoking | 2 | 2015 | 651 | 0.160 |
Why?
|
| Cerebellar Ataxia | 1 | 2020 | 27 | 0.160 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 426 | 0.160 |
Why?
|
| Cardiac Conduction System Disease | 1 | 2020 | 8 | 0.160 |
Why?
|
| Thoracic Injuries | 1 | 2020 | 41 | 0.160 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2021 | 161 | 0.160 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2020 | 52 | 0.160 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2020 | 8 | 0.160 |
Why?
|
| Morphinans | 1 | 2019 | 4 | 0.160 |
Why?
|
| Patient Care Management | 1 | 2020 | 30 | 0.160 |
Why?
|
| Uterine Diseases | 1 | 2020 | 19 | 0.160 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2020 | 89 | 0.160 |
Why?
|
| Electric Countershock | 2 | 2018 | 77 | 0.160 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 56 | 0.160 |
Why?
|
| Streptococcus pneumoniae | 1 | 2020 | 56 | 0.160 |
Why?
|
| Bone Marrow | 1 | 2021 | 415 | 0.160 |
Why?
|
| Acute Disease | 2 | 2021 | 859 | 0.150 |
Why?
|
| Infant, Newborn | 5 | 2018 | 2611 | 0.150 |
Why?
|
| Community-Acquired Infections | 1 | 2020 | 65 | 0.150 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 84 | 0.150 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2021 | 84 | 0.150 |
Why?
|
| Sexual and Gender Minorities | 1 | 2023 | 250 | 0.150 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2020 | 118 | 0.150 |
Why?
|
| Cardiomyopathies | 2 | 2015 | 318 | 0.150 |
Why?
|
| Child, Preschool | 7 | 2024 | 3969 | 0.150 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2019 | 68 | 0.150 |
Why?
|
| Adolescent | 7 | 2024 | 9878 | 0.150 |
Why?
|
| Hypoglycemic Agents | 2 | 2018 | 376 | 0.140 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2018 | 1 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 249 | 0.140 |
Why?
|
| Prescription Drugs | 1 | 2019 | 39 | 0.140 |
Why?
|
| Guideline Adherence | 3 | 2021 | 245 | 0.140 |
Why?
|
| Age Factors | 7 | 2021 | 1959 | 0.140 |
Why?
|
| Naltrexone | 1 | 2019 | 139 | 0.140 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 2018 | 31 | 0.140 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 318 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 468 | 0.140 |
Why?
|
| Urban Health Services | 2 | 2011 | 47 | 0.140 |
Why?
|
| Sympathectomy | 2 | 2015 | 19 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 790 | 0.140 |
Why?
|
| Premenopause | 1 | 2018 | 63 | 0.140 |
Why?
|
| Narcotic Antagonists | 1 | 2019 | 170 | 0.140 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2018 | 146 | 0.140 |
Why?
|
| Luteinizing Hormone | 1 | 2018 | 168 | 0.140 |
Why?
|
| Informed Consent By Minors | 1 | 2017 | 2 | 0.140 |
Why?
|
| Pregnancy | 2 | 2016 | 3239 | 0.140 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 51 | 0.130 |
Why?
|
| Antidiarrheals | 1 | 2017 | 14 | 0.130 |
Why?
|
| Dyslipidemias | 1 | 2018 | 109 | 0.130 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2018 | 50 | 0.130 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 151 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 376 | 0.130 |
Why?
|
| Mental Competency | 1 | 2017 | 50 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 2042 | 0.130 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2017 | 106 | 0.130 |
Why?
|
| Weight Loss | 1 | 2018 | 240 | 0.130 |
Why?
|
| Cholesterol | 1 | 2019 | 367 | 0.130 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 228 | 0.130 |
Why?
|
| Observational Studies as Topic | 1 | 2017 | 56 | 0.130 |
Why?
|
| Social Perception | 1 | 1997 | 94 | 0.120 |
Why?
|
| Probiotics | 1 | 2017 | 92 | 0.120 |
Why?
|
| Causality | 1 | 2016 | 84 | 0.120 |
Why?
|
| Recovery of Function | 1 | 2018 | 348 | 0.120 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2018 | 208 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2017 | 159 | 0.120 |
Why?
|
| Incidence | 5 | 2024 | 1723 | 0.120 |
Why?
|
| Physician's Role | 1 | 1997 | 186 | 0.110 |
Why?
|
| Cause of Death | 1 | 2016 | 279 | 0.110 |
Why?
|
| Pharmacogenetics | 1 | 2019 | 457 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 346 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 334 | 0.110 |
Why?
|
| Primary Prevention | 2 | 2024 | 87 | 0.110 |
Why?
|
| Blood Glucose | 1 | 2018 | 873 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2017 | 387 | 0.110 |
Why?
|
| Aged | 9 | 2016 | 20927 | 0.110 |
Why?
|
| Pressure Ulcer | 2 | 2013 | 44 | 0.110 |
Why?
|
| Life Expectancy | 1 | 2014 | 91 | 0.110 |
Why?
|
| Advisory Committees | 1 | 2014 | 94 | 0.100 |
Why?
|
| Hepacivirus | 1 | 2015 | 137 | 0.100 |
Why?
|
| Documentation | 2 | 2013 | 103 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 880 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1618 | 0.100 |
Why?
|
| Aging | 1 | 1999 | 766 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2017 | 926 | 0.100 |
Why?
|
| Critical Care | 1 | 2017 | 448 | 0.100 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2013 | 67 | 0.100 |
Why?
|
| Hospitalization | 3 | 2016 | 946 | 0.100 |
Why?
|
| Ventricular Fibrillation | 1 | 2013 | 78 | 0.100 |
Why?
|
| Teaching | 2 | 2011 | 154 | 0.100 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 2012 | 13 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2013 | 346 | 0.090 |
Why?
|
| Heart Arrest | 2 | 2013 | 313 | 0.090 |
Why?
|
| Checklist | 1 | 2013 | 73 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2016 | 566 | 0.090 |
Why?
|
| Epilepsy | 1 | 2016 | 452 | 0.090 |
Why?
|
| Communication | 2 | 2019 | 478 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2018 | 10307 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 848 | 0.090 |
Why?
|
| Education | 1 | 2011 | 61 | 0.090 |
Why?
|
| Syncope | 2 | 2022 | 37 | 0.090 |
Why?
|
| Patients | 1 | 2012 | 109 | 0.090 |
Why?
|
| Chest Pain | 2 | 2022 | 49 | 0.090 |
Why?
|
| Primary Health Care | 3 | 2011 | 391 | 0.080 |
Why?
|
| Patient Handoff | 1 | 2012 | 100 | 0.080 |
Why?
|
| Medical Informatics Applications | 1 | 2010 | 9 | 0.080 |
Why?
|
| Time Factors | 5 | 2021 | 5593 | 0.080 |
Why?
|
| Probability | 2 | 2022 | 365 | 0.080 |
Why?
|
| Patient Transfer | 1 | 2011 | 108 | 0.080 |
Why?
|
| Cost of Illness | 1 | 2011 | 161 | 0.080 |
Why?
|
| Awareness | 1 | 2010 | 90 | 0.080 |
Why?
|
| Albuminuria | 1 | 2010 | 51 | 0.080 |
Why?
|
| Continuity of Patient Care | 1 | 2011 | 180 | 0.080 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2010 | 62 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2022 | 4690 | 0.080 |
Why?
|
| Sigmoidoscopy | 1 | 1989 | 38 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2011 | 182 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2018 | 1176 | 0.070 |
Why?
|
| Liver | 2 | 2024 | 1231 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2010 | 175 | 0.070 |
Why?
|
| Minority Groups | 2 | 2007 | 154 | 0.070 |
Why?
|
| Mutation | 1 | 2020 | 4374 | 0.070 |
Why?
|
| Young Adult | 4 | 2024 | 7034 | 0.070 |
Why?
|
| New Zealand | 2 | 2020 | 24 | 0.070 |
Why?
|
| Neoplasms | 1 | 2024 | 3242 | 0.070 |
Why?
|
| Hospitalists | 1 | 2010 | 143 | 0.070 |
Why?
|
| Telemedicine | 1 | 2011 | 229 | 0.070 |
Why?
|
| Inpatients | 1 | 2011 | 348 | 0.070 |
Why?
|
| Heart Failure | 1 | 2018 | 1438 | 0.070 |
Why?
|
| Mandatory Reporting | 1 | 2007 | 7 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2022 | 3115 | 0.070 |
Why?
|
| Reimbursement, Incentive | 1 | 2007 | 39 | 0.070 |
Why?
|
| Patient Discharge | 1 | 2010 | 363 | 0.060 |
Why?
|
| Program Development | 1 | 2007 | 136 | 0.060 |
Why?
|
| Hospitals, Teaching | 3 | 2011 | 119 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 231 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2017 | 2603 | 0.060 |
Why?
|
| Prognosis | 3 | 2021 | 3993 | 0.060 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2024 | 8 | 0.050 |
Why?
|
| Hepatitis B Vaccines | 1 | 2024 | 18 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2024 | 9228 | 0.050 |
Why?
|
| Hepatitis B, Chronic | 1 | 2024 | 34 | 0.050 |
Why?
|
| Thymidylate Synthase | 1 | 2024 | 14 | 0.050 |
Why?
|
| Hepatitis C, Chronic | 1 | 2024 | 96 | 0.050 |
Why?
|
| Solar System | 1 | 2023 | 1 | 0.050 |
Why?
|
| Disease Progression | 2 | 2018 | 1561 | 0.050 |
Why?
|
| Silicates | 1 | 2023 | 10 | 0.050 |
Why?
|
| Intensive Care Units | 2 | 2021 | 460 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 7224 | 0.050 |
Why?
|
| Analgesics | 2 | 2021 | 132 | 0.050 |
Why?
|
| Age of Onset | 1 | 2024 | 345 | 0.050 |
Why?
|
| Gender Identity | 1 | 2023 | 60 | 0.050 |
Why?
|
| Phenotype | 2 | 2020 | 2575 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2012 | 1134 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 3922 | 0.050 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2022 | 26 | 0.050 |
Why?
|
| Uricosuric Agents | 1 | 2021 | 11 | 0.050 |
Why?
|
| American Cancer Society | 1 | 2021 | 13 | 0.050 |
Why?
|
| Hydroxyethyl Starch Derivatives | 1 | 2021 | 7 | 0.040 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2021 | 35 | 0.040 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 33 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2024 | 550 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2010 | 1018 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 68 | 0.040 |
Why?
|
| Uric Acid | 1 | 2021 | 137 | 0.040 |
Why?
|
| Norepinephrine | 1 | 2021 | 173 | 0.040 |
Why?
|
| Chicago | 3 | 1997 | 1505 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 983 | 0.040 |
Why?
|
| Exercise | 1 | 2024 | 355 | 0.040 |
Why?
|
| Transgender Persons | 1 | 2023 | 132 | 0.040 |
Why?
|
| Logistic Models | 2 | 2011 | 1273 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2024 | 504 | 0.040 |
Why?
|
| Watchful Waiting | 1 | 2021 | 71 | 0.040 |
Why?
|
| Aorta | 1 | 2021 | 294 | 0.040 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 334 | 0.040 |
Why?
|
| Manipulation, Orthopedic | 1 | 1999 | 5 | 0.040 |
Why?
|
| Echocardiography | 2 | 2021 | 1010 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 12 | 0.040 |
Why?
|
| Low Back Pain | 1 | 1999 | 59 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 263 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2024 | 2042 | 0.040 |
Why?
|
| Plants, Toxic | 1 | 1999 | 25 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 346 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 1819 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2021 | 463 | 0.030 |
Why?
|
| Electronic Health Records | 2 | 2013 | 373 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 372 | 0.030 |
Why?
|
| Pharmacogenomic Testing | 1 | 2019 | 107 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2024 | 922 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 1997 | 39 | 0.030 |
Why?
|
| Self Disclosure | 1 | 1997 | 32 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 156 | 0.030 |
Why?
|
| Research | 1 | 2019 | 265 | 0.030 |
Why?
|
| Personality Inventory | 1 | 1997 | 112 | 0.030 |
Why?
|
| Health Promotion | 1 | 1999 | 176 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 284 | 0.030 |
Why?
|
| Health Personnel | 1 | 1999 | 241 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1997 | 365 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 1997 | 295 | 0.030 |
Why?
|
| Mental Recall | 1 | 1997 | 173 | 0.030 |
Why?
|
| Autopsy | 1 | 2016 | 127 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 210 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 386 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1997 | 909 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2019 | 456 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 677 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 33 | 0.020 |
Why?
|
| Catheter-Related Infections | 1 | 2013 | 24 | 0.020 |
Why?
|
| Cognition | 1 | 1997 | 635 | 0.020 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2013 | 81 | 0.020 |
Why?
|
| Ventricular Remodeling | 1 | 2013 | 114 | 0.020 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 129 | 0.020 |
Why?
|
| Patient Satisfaction | 2 | 2010 | 514 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2013 | 119 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 1355 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2013 | 262 | 0.020 |
Why?
|
| Hypnotics and Sedatives | 1 | 2013 | 142 | 0.020 |
Why?
|
| Videoconferencing | 1 | 2011 | 20 | 0.020 |
Why?
|
| Canada | 1 | 2012 | 214 | 0.020 |
Why?
|
| Models, Educational | 1 | 2011 | 51 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2011 | 48 | 0.020 |
Why?
|
| Global Health | 1 | 2013 | 214 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 155 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 1997 | 1880 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 890 | 0.020 |
Why?
|
| Bedding and Linens | 1 | 2011 | 16 | 0.020 |
Why?
|
| Personnel, Hospital | 1 | 2011 | 32 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 905 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 64 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2011 | 61 | 0.020 |
Why?
|
| Patient Preference | 1 | 2011 | 126 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 258 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 221 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 1541 | 0.020 |
Why?
|
| Frail Elderly | 1 | 2010 | 92 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 600 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1741 | 0.020 |
Why?
|
| Patient Participation | 1 | 2011 | 241 | 0.020 |
Why?
|
| Perception | 1 | 2010 | 185 | 0.020 |
Why?
|
| Psychometrics | 1 | 2010 | 340 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2010 | 362 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2012 | 371 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 2860 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 936 | 0.020 |
Why?
|
| Data Collection | 1 | 1989 | 381 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 721 | 0.020 |
Why?
|
| Program Evaluation | 1 | 1989 | 323 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 2474 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 1989 | 500 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2007 | 376 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2011 | 858 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 1989 | 587 | 0.010 |
Why?
|
| Medically Underserved Area | 1 | 2004 | 27 | 0.010 |
Why?
|
| Ventricular Dysfunction | 1 | 2004 | 28 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 1997 | 3155 | 0.010 |
Why?
|
| Medicare | 1 | 2006 | 458 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 819 | 0.010 |
Why?
|
| Manipulation, Spinal | 1 | 1999 | 2 | 0.010 |
Why?
|
| Physical Therapy Modalities | 1 | 1999 | 93 | 0.010 |
Why?
|
| Mammography | 1 | 1997 | 475 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1997 | 2885 | 0.010 |
Why?
|